Diabetic CKD G3b-A3: Advanced Multidisciplinary Management Case

NEPHROHUB • ADVANCED INTERACTIVE CASE

Educational disclaimer: This postgraduate case is for education and does not replace bedside assessment, local protocols, senior nephrology input, current prescribing information, or patient-specific evaluation.

Difficulty and format

Difficulty: Advanced. Format: Four-stage longitudinal decision case focused on CKD classification, diabetic kidney disease therapy, medication safety, blood-pressure management, complications, and shared multidisciplinary care.

Learning objectives

By the end of this case, learners should be able to classify CKD using cause, GFR, and albuminuria; recognize that UACR 320 mg/g is A3 albuminuria; assess whether an eGFR decline is chronic, hemodynamic, or acute; optimize foundational therapy with individualized safety monitoring; interpret BP targets using standardized measurement; and manage anemia and CKD-MBD abnormalities by trends and reversible causes rather than isolated thresholds.

Stage 1 — Confirm the phenotype and trajectory

Presentation

Maria Rodriguez is a 62-year-old retired elementary-school teacher with 15 years of type 2 diabetes, hypertension, hyperlipidemia, obesity, mild diabetic retinopathy, and knee osteoarthritis. Her creatinine is 1.6 mg/dL and eGFR 38 mL/min/1.73 m², compared with creatinine 1.3 and eGFR 45 six months earlier. UACR is 320 mg/g, potassium 4.8 mEq/L, hemoglobin 11.2 g/dL, calcium 9.2 mg/dL, phosphate 4.0 mg/dL, PTH 85 pg/mL, and 25-OH vitamin D 22 ng/mL. BP is 142/88 mmHg. HbA1c is 7.8%.

She takes metformin 1000 mg twice daily, glipizide 10 mg daily, lisinopril 20 mg daily, atorvastatin 40 mg daily, and aspirin 81 mg daily. She reports fatigue, reduced activity, occasional dietary indiscretions, and home glucose values of 130–180 mg/dL.

Decision point 1 — What should be confirmed first?

Preferred decision: Confirm chronicity and trajectory, repeat UACR under appropriate conditions, review adherence and volume status, check for intercurrent illness and nephrotoxins, and evaluate cause using the diabetic retinopathy, albuminuria pattern, urine sediment, and clinical history. If chronicity is confirmed, the phenotype is diabetic CKD G3b-A3, not G3b-A2, because UACR 320 mg/g is severely increased albuminuria.

A six-month eGFR decline from 45 to 38 warrants review but is not automatically an irreversible progression rate. Repeat creatinine/eGFR and potassium, review NSAID exposure and over-the-counter products, examine urine sediment when indicated, and consider cystatin C when greater GFR precision would change a decision. Rapid progression, atypical features, active sediment, abrupt proteinuria, or discordance with the presumed cause should prompt nephrology-led evaluation.

Stage 2 — Optimize kidney-protective pharmacotherapy safely

Decision point 2 — Which medication strategy is most appropriate?

Preferred decision: Continue or adjust metformin only after reviewing dose, acute-illness risk, nutrition, and local labeling; metformin should not be used when eGFR is below 30 mL/min/1.73 m², and dose reduction or closer review is appropriate in the eGFR 30–44 range. Offer an SGLT2 inhibitor for eligible T2D and CKD after reviewing eGFR thresholds, volume status, genital-infection risk, ketoacidosis risk, and sick-day/perioperative instructions. Explain that a small initial eGFR dip can occur and that the drug should be reviewed during acute illness or prolonged fasting.

A long-acting GLP-1 receptor agonist may be considered if additional glycemic, weight, or cardiovascular-risk management is needed after foundational therapy or when SGLT2 therapy is not suitable. Its kidney-outcome evidence is agent- and evidence-dependent rather than a universal guarantee. Review glipizide-related hypoglycemia risk as kidney function and food intake change.

Safety branch — What requires earlier reassessment?

An acute creatinine rise, symptomatic hypotension, dehydration, severe genital infection, unexplained metabolic acidosis, ketones, or recurrent hypoglycemia should prompt same-day clinical review and medication adjustment according to local protocol. Renal-protective therapy should not be stopped reflexively for every minor creatinine change, but safety reassessment is mandatory.

Stage 3 — Manage BP, albuminuria, and complications

Decision point 3 — How should BP and RAS therapy be approached?

Confirm BP using standardized office technique and complementary home readings. Because she has diabetic CKD with A3 albuminuria, continue ACE inhibitor therapy and titrate toward the highest tolerated approved dose if potassium, creatinine, orthostasis, and adherence permit. After dose changes, recheck creatinine and potassium according to local protocol. If BP remains above the individualized goal, add a long-acting dihydropyridine calcium-channel blocker or appropriate diuretic rather than combining ACE inhibitor and ARB.

KDIGO BP guidance supports intensive systolic control in suitable non-dialysis CKD patients when standardized measurement is used and treatment is tolerated; frailty, orthostasis, falls, and patient preference modify the goal. Encourage sodium intake below approximately 2 g/day when feasible, with culturally appropriate dietitian support.

Complication branch — anemia and CKD-MBD

Her hemoglobin of 11.2 g/dL does not justify ESA therapy. Evaluate anemia using CBC indices, reticulocytes, ferritin, TSAT, B12/folate and other tests guided by context. Treat iron deficiency or other reversible causes first; ESA decisions are individualized and nephrology-led rather than triggered by a single Hb threshold.

Her mildly elevated PTH and low 25-OH vitamin D require trend-based interpretation with calcium, phosphate, alkaline phosphatase, dietary intake, and vitamin-D status. Correct documented vitamin-D deficiency using a local regimen, but do not present 50,000 IU weekly for eight weeks as a universal protocol. CKD-MBD treatment should avoid inappropriate calcium loading and respond to persistent, clinically meaningful abnormalities.

Stage 4 — Build longitudinal multidisciplinary care

Decision point 4 — What should the shared plan include?

Maria should receive nephrology co-management because of eGFR decline, A3 albuminuria, diabetes, medication complexity, and possible need to clarify cause and progression. Primary care, nephrology, diabetes education, dietetics, pharmacy, and the patient should agree on a risk-based monitoring plan. Repeat eGFR, UACR, potassium, HbA1c, BP, medication safety tests, hemoglobin, and CKD-MBD markers at intervals determined by risk and recent treatment changes rather than a fixed universal three-month rule.

Set individualized glycemic and BP goals. Avoid universal home glucose or weight-gain thresholds; define hypoglycemia precautions, sick-day instructions, relevant fluid-overload red flags, NSAID avoidance, exercise adapted to knee pain, and a clear route for urgent review.

Follow-up branch

At three months, eGFR is 39, UACR 220 mg/g, standardized BP 128/76 mmHg, and HbA1c 7.2%. At six months, eGFR is 40, UACR 180 mg/g, BP 126/74 mmHg, and HbA1c 7.0%. These are plausible monitored outcomes, not guaranteed treatment effects. Vitamin D and PTH improve after individualized deficiency management and dietary review. The team continues surveillance because stabilization does not eliminate future CKD, cardiovascular, hypoglycemia, or medication-toxicity risk.

Expert synthesis

This patient has presumed diabetic CKD G3b-A3 after chronicity and cause are confirmed. Priorities are risk-based assessment, ACE inhibitor or ARB therapy at the highest tolerated approved dose with potassium and creatinine monitoring, SGLT2 inhibitor therapy when eligible, individualized glycemic therapy, standardized BP assessment, sodium reduction, nephrotoxin avoidance, and coordinated longitudinal care. GLP-1 receptor agonists may provide glycemic, weight, and cardiovascular benefits, with kidney outcome claims kept agent- and evidence-specific. Anemia and CKD-MBD abnormalities require trend and reversible-cause assessment rather than automatic ESA or fixed vitamin-D regimens.

Advanced Self-Assessment

Complete the accompanying ten-question Advanced assessment. Detailed explanations are provided after submission.

Advanced Self-Assessment: Diabetic CKD G3b-A3

1 / 10

Maria’s repeat UACR remains 320 mg/g and chronicity is confirmed. How should her CKD be classified using the KDIGO CGA framework?

G3b-A1 diabetic CKD

G3b-A3 CKD because UACR 320 mg/g is severely increased albuminuria

G3b-A2 CKD because all albuminuria below 500 mg/g is moderate

G4-A3 CKD because eGFR has fallen from 45 to 38

2 / 10

Which is the most appropriate way to address Maria’s metformin prescription?

Continue 1000 mg twice daily indefinitely because metformin is not renally cleared.

Stop metformin immediately in every patient whose eGFR is below 45.

Review dose and acute-illness precautions, consider dose reduction according to local labeling and risk, and discontinue if eGFR falls below 30 or a contraindication develops.

Replace metformin with a sulfonylurea at a higher dose as the default renal strategy.

3 / 10

Which statement best describes offering an SGLT2 inhibitor to Maria?

It is a kidney-protective option for eligible T2D and CKD, with counseling about eGFR thresholds, volume status, genital infections, ketoacidosis risk, and temporary holding during selected acute illnesses or fasting.

It should be avoided because SGLT2 inhibitors are ineffective once eGFR is below 45.

It should be started only after UACR falls below 30 mg/g.

It should be used as emergency treatment for an acute creatinine rise.

4 / 10

Maria remains obese with HbA1c above her individualized goal after foundational therapy. Which is the most accurate statement about a long-acting GLP-1 receptor agonist?

It should replace ACE inhibitor therapy because it is the primary albuminuria treatment.

It has no role in CKD because all GLP-1 receptor agonists are nephrotoxic.

It should be prescribed solely to normalize PTH.

It may be considered for additional glycemic, weight, or cardiovascular-risk management; kidney-outcome claims should remain agent- and evidence-specific.

5 / 10

Maria’s standardized BP remains above her individualized goal, potassium is stable, and there is no orthostasis. What is the best next approach?

Combine lisinopril with an ARB to maximize albuminuria reduction.

Titrate the ACE inhibitor toward the highest tolerated approved dose, then recheck creatinine and potassium and add another class if needed.

Stop RAS blockade because any creatinine change is harmful.

Add a potassium supplement before increasing lisinopril.

6 / 10

Which statement best reflects contemporary CKD BP management for Maria?

A single routine clinic BP of 142/88 proves that the target must be exactly 130/80 for every patient.

BP goals are irrelevant once an SGLT2 inhibitor is started.

Use standardized office measurement and home readings, pursue an individualized goal that may include intensive systolic control when tolerated, and account for orthostasis, frailty, falls, and patient preference.

Increase all antihypertensives until the patient’s systolic BP is below 90 mmHg.

7 / 10

Maria’s hemoglobin is 11.2 g/dL with fatigue. What is the most appropriate next step?

Evaluate CBC indices, reticulocytes, ferritin, TSAT, B12/folate and other reversible causes; do not start an ESA solely because fatigue is present.

Start an ESA immediately because Hb is below 12 g/dL.

Start an ESA once Hb is below 10 g/dL without further evaluation.

Transfuse routinely to maintain Hb above 12 g/dL.

8 / 10

Maria has calcium 9.2 mg/dL, phosphate 4.0 mg/dL, PTH 85 pg/mL, and 25-OH vitamin D 22 ng/mL. Which management is most appropriate?

Start a fixed high-dose active vitamin-D analogue solely because PTH is above the laboratory range.

Begin calcium loading until PTH becomes normal.

Ignore the findings because CKD G3b cannot develop CKD-MBD.

Correct documented nutritional vitamin-D deficiency using a local regimen and interpret serial calcium, phosphate, PTH, alkaline phosphatase, and vitamin-D results together.

9 / 10

Which referral and monitoring plan is most appropriate?

Wait until eGFR is below 15 because albuminuria does not affect referral.

Refer or co-manage now because of eGFR decline, A3 albuminuria, diabetes, medication complexity, and need for cause and risk evaluation; use risk-based monitoring rather than a universal interval.

Refer only if hemoglobin falls below 10 g/dL.

Arrange one annual creatinine test because the patient is not yet in G4.

10 / 10

Which plan best represents high-quality multidisciplinary care for Maria?

Focus only on HbA1c and stop kidney surveillance once UACR improves.

Use fixed glucose, BP, weight, vitamin-D, and ESA thresholds for every patient regardless of symptoms or comorbidity.

Combine kidney-protective therapy, individualized glycemic and BP goals, medication-safety monitoring, anemia/CKD-MBD trend assessment, diet and exercise support, nephrotoxin avoidance, shared decision-making, and clear sick-day/red-flag instructions.

Transfer all care to nephrology and discontinue primary-care and diabetes education input.

Your score is

The average score is 0%

By Wordpress Quiz plugin

References

KDIGO 2022 Diabetes Management in CKD guideline resources.
[inline_viewer url="https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf"].
ERBP commentary on KDIGO 2024 CKD guideline.
KDIGO CKD-MBD guideline resources.
[inline_viewer url="https://kdigo.org/wp-content/uploads/2023/04/Diabetes-Management-in-Chronic-Kidney-Disease-Consensus-Report-by-the-ADA-KDIGO.pdf"].

NephroHub — postgraduate clinical education in nephrology.